We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Based in Lorrach, Germany and Saint Louis, France, Allecra Therapeutics releasedpositive top-line data from its Phase II trial of AAI101, an antibiotic against gram-negative bacteria.